Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic version of Syprine®1 (trientine hydrochloride) capsules, 250 mg, in the U.S.
Latest News & Announcements
From Wilson Disease Association
Teva Announces Launch of a Generic Version of Syprine® in the United States
- Details
- Written by JERUSALEM--(BUSINESS WIRE)
- Category: Latest
- Hits: 10301
Search Our Site
Copyright ©
1978 - 2025
The Wilson Disease Association
This website is not intended to provide advice on personal medical matters or to substitute for consultation with a physician. The WDA does not accept advertising for this website.
1732 First Avenue #20043. New York, NY. 10128 | 866-961-0533 or 414-961-0533
Terms of Use